Heterocyclic inhibitors of ERK2 and uses thereof
US7304061B2 · kind B2 · utility
55Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 25, 2003 |
| Grant date | Dec 4, 2007 |
| Priority date | — |
| Expiry date | Sep 8, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Described herein are compounds that are useful as protein kinase inhibitors having the formula:wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.